OncoSec signs definitive agreements to purchase $7.5 million of securities in registe
 

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.5 million of securities in a registered direct offering.

More...